1
|
Madanat L, Allam M, Khalili H, Rabah A, Tariq R, Zamzam M, Rodés-Cabau J, Pilgrim T, Okuno T, Elmariah S, Pibarot P, Abbas AE. Long-Term Survival and Quality of Life Following Transcatheter Aortic Valve Replacement in Nonagenarians. Am J Cardiol 2024; 213:140-145. [PMID: 38134979 DOI: 10.1016/j.amjcard.2023.12.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Revised: 11/16/2023] [Accepted: 12/17/2023] [Indexed: 12/24/2023]
Abstract
Transcatheter aortic valve replacement (TAVR) has emerged as a successful treatment option for severe aortic stenosis. However, the long-term outcomes of TAVR in nonagenarians is lacking. We aimed to examine the long-term mortality and quality of life in nonagenarians after TAVR. This is a multicenter, retrospective analysis on patients with severe aortic stenosis who underwent TAVR. Patients were divided into 2 groups: nonagenarians (age ≥90 years) and age <90 years. The Kansas City cardiomyopathy questionnaire (KCCQ) and New York Heart Association (NYHA) scores were compared before and after TAVR. All-cause mortality was compared between both groups at 30 days, 1 year, and 5 years after TAVR using the Cox proportional hazard model. A total of 6,896 patients were included, of whom 591 were nonagenarians. Nonagenarians had a higher Society of Thoracic Surgeons perioperative risk of mortality (8.1 ± 4.6% vs 5.4 ± 4.2%, p <0.001) before TAVR. Both groups were similar in KCCQ and NYHA scores at baseline. At 1 year after TAVR, there was no significant difference in improvement in the KCCQ overall score between those aged <90 years and nonagenarians (-4.76, 95% confidence interval [CI] -11.4 to 1.9, p = 0.161). Similarly, there was no statistically significant difference in improvement in NYHA class between the 2 groups at 1 year (odds ratio 1.07, 95% CI 0.85 to 1.25), p = 0.526). The unadjusted 30-day (3.2% vs 2.7%, hazard ratio 1.11, 95% CI 0.70 to 1.80, p = 0.667) and 5-year (28.0% vs 26.6%, hazard ratio 1.05, 95% CI 0.89 to 1.24, p = 0.60) all-cause mortality were similar between the 2 groups. In conclusion, this study demonstrates an excellent long-term mortality rate at 5 years after TAVR in nonagenarians, comparable to patients younger than 90 years. There is a significant and enduring improvement in functional status in nonagenarians, observed up to 1 year after TAVR.
Collapse
Affiliation(s)
- Luai Madanat
- William Beaumont University Hospital, Corewell Health East, Michigan
| | - Mohamed Allam
- William Beaumont University Hospital, Corewell Health East, Michigan
| | - Houman Khalili
- Florida Atlantic University, Boca Raton, Florida; Memorial Cardiovascular Institute, Hollywood, Florida
| | - Andrew Rabah
- Oakland University William Beaumont School of Medicine, Rochester, Michigan
| | - Rehan Tariq
- Oakland University William Beaumont School of Medicine, Rochester, Michigan
| | - Mazen Zamzam
- Oakland University William Beaumont School of Medicine, Rochester, Michigan
| | - Josep Rodés-Cabau
- Université Laval, Québec, Canada; Québec Heart and Lung Institute, Québec, Canada
| | | | | | | | - Philippe Pibarot
- Université Laval, Québec, Canada; Québec Heart and Lung Institute, Québec, Canada
| | - Amr E Abbas
- William Beaumont University Hospital, Corewell Health East, Michigan; Oakland University William Beaumont School of Medicine, Rochester, Michigan.
| |
Collapse
|
2
|
Ismayl M, Abbasi MA, Al-Abcha A, Robertson S, El-Am E, Goldsweig AM, Alkhouli M, Guerrero M, Anavekar NS. Outcomes of Transcatheter Aortic Valve Implantation in Nonagenarians and Octogenarians (Analysis from the National Inpatient Sample Database). Am J Cardiol 2023; 199:59-70. [PMID: 37257370 DOI: 10.1016/j.amjcard.2023.04.049] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 03/30/2023] [Accepted: 04/13/2023] [Indexed: 06/02/2023]
Abstract
Risks among nonagenarian (age ≥90 years) and octogenarian (age 80 to 89 years) patients who underwent transcatheter aortic valve implantation (TAVI) compared with clinically similar septuagenarian (age 70 to 79 years) patients remain unclear. This study aimed to assess the outcomes of TAVI in nonagenarians and octogenarians compared with septuagenarians. We conducted a retrospective cohort study using the National Inpatient Sample database to identify patients aged ≥70 years hospitalized for TAVI from 2016 to 2020 and to compare outcomes in nonagenarians and octogenarians versus septuagenarians. The primary outcome was in-hospital mortality. Secondary outcomes included procedural complications, length of stay (LOS), and total costs. The trends in in-hospital outcomes were evaluated. Results were adjusted for demographic/clinical factors. The total cohort included 263,325 patients hospitalized for TAVI, of whom 11.9% were nonagenarians, 51.1% octogenarians, and 37.0% septuagenarians. After adjustment, nonagenarians and octogenarians had higher odds of in-hospital mortality (adjusted odds ratio 1.80, 95% confidence interval 1.34 to 2.41 for nonagenarians; adjusted odds ratio 1.65, 95% confidence interval 1.35 to 2.01 for octogenarians), heart block, permanent pacemaker insertion, stroke, major bleeding, blood transfusion, and palliative care consultation than septuagenarians (all p <0.01). LOS was longer and the total costs were higher for nonagenarians and octogenarians (both p <0.01). Over the study period, in-hospital mortality decreased in nonagenarians (ptrend = 0.04), and major bleeding, permanent pacemaker insertion, LOS, and costs decreased in all patients aged ≥70 years (ptrend <0.01). In conclusion, nonagenarians and octogenarians who underwent TAVI have higher rates of mortality and procedure-related complications than clinically similar septuagenarians. Further research is necessary to optimize outcomes in this frail population.
Collapse
Affiliation(s)
- Mahmoud Ismayl
- Department of Internal Medicine, Creighton University School of Medicine, Omaha, Nebraska.
| | | | - Abdullah Al-Abcha
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| | - Sam Robertson
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
| | - Edward El-Am
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| | - Andrew M Goldsweig
- Department of Cardiovascular Medicine, Baystate Medical Center, Springfield, Massachusetts
| | - Mohamad Alkhouli
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| | - Mayra Guerrero
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| | - Nandan S Anavekar
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
3
|
Haum M, Humpfer F, Steffen J, Fischer J, Stocker TJ, Sadoni S, Theiss H, Braun D, Orban M, Rizas K, Massberg S, Hausleiter J, Deseive S. Quantification of physical activity with prospective activity tracking after transfemoral aortic valve replacement. Int J Cardiol 2023; 376:100-107. [PMID: 36758861 DOI: 10.1016/j.ijcard.2023.01.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Revised: 01/11/2023] [Accepted: 01/31/2023] [Indexed: 02/10/2023]
Abstract
BACKGROUND Transcatheter aortic valve replacement (TAVR) is a well-established, safe and effective therapy for severe symptomatic aortic stenosis (AS). The aim of this study was to objectively quantify improvement of physical activity after TAVR, with consideration of different low-gradient AS subtypes. METHODS AND RESULTS All patients undergoing TAVR for severe AS were screened. Participants received a wearable activity tracker (Fitbit®) at hospital discharge following TAVR and 6 months thereafter. The difference of median daily steps was defined as surrogate outcome for physical activity. For analysis, patients were grouped into high-gradient (HG) AS (dPmean ≥40 mmHg), classical low-flow low-gradient (LFLG) AS (dPmean <40 mmHg, EF <50%), paradoxical LFLG-AS (dPmean <40 mmHg, EF ≥50%, SVi ≤35 ml/m2) and normal-flow low-gradient (NFLG) AS (dPmean <40 mmHg, EF ≥50%, SVi >35 ml/m2) according to mean transvalvular pressure gradient (dPmean), stroke volume index (SVi) and left-ventricular ejection fraction (LVEF). RESULTS AND CONCLUSIONS The analysis is based on 230 patients. The median daily step count was 4409 [IQR 2581-7487] after hospital discharge and 5326 [IQR 3045-8668] 6 months thereafter. Median difference of daily steps was ∆529 [IQR -702-2152]). Patients with HG-AS and paradoxical LFLG-AS showed a significant improvement of daily steps (∆951 [IQR -378-2323], p <0.001 and (∆1392 [IQR -609-4444], p = 0.02, respectively). Patients with classical LFLG-AS showed no statistically relevant improvement of daily steps (∆192 [IQR -687-770], p = 0.79). Patients with NFLG-AS showed a numerical decline in daily steps without statistical significance (∆-300 [IQR -1334-1406], p = 0.67). This first prospective study of this sample size shows significant improvement of physical activity after TAVR with an objective and reproducible method. This was mainly driven by an improvement in patients with HG-AS and paradoxical LFLG-AS.
Collapse
Affiliation(s)
- Magda Haum
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Fabian Humpfer
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany
| | - Julius Steffen
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Julius Fischer
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Thomas J Stocker
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Sebastian Sadoni
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany
| | - Hans Theiss
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Daniel Braun
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Martin Orban
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Konstantinos Rizas
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Steffen Massberg
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Jörg Hausleiter
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany; German Centre for Cardiovascular Research (DZHK), partner site Munich, Germany
| | - Simon Deseive
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, LMU München, Marchioninistr. 15, 81377 Munich, Germany.
| |
Collapse
|
4
|
Güzel T, Demir M, Aktan A, Arık B, Argun L, İldırımlı K, Sütcü M, Arslan B, Özbek M, Kılıç R, Aslan B, Gitmez M, Karaçalılar M, Çakır Ç, Ertaş F. A new trend to reduce adverse events in patients undergoing transcatheter aortic valve implantation: cusp overlap technique: a cross sectional study. Aging Clin Exp Res 2023; 35:375-385. [PMID: 36460902 DOI: 10.1007/s40520-022-02307-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2022] [Accepted: 11/15/2022] [Indexed: 12/03/2022]
Abstract
BACKGROUND Transcatheter aortic valve implantation (TAVI) is currently the treatment of choice for the majority of patients at moderate or high surgical risk. However, some complications occur frequently with this procedure. In this study, we aimed to assess whether the cusp-overlap view (COP) technique may be associated with a reduced incidence of some of these complications compared with the classical three-cusp view (TCV) technique. METHODS In this single-center, retrospective study we investigated; technical success, postprocedural permanent pacemaker implantation (PPMI), new-onset stroke, pericardial tamponade, arrhythmia development, acute renal failure, major bleeding, major vascular complications, procedure-related coronary obstruction, new-onset left bundle branch block (LBBB), paravalvular leak, peri-procedural myocardial infarction (MI), day of hospitalization, death, and major adverse cardiac and cerebrovascular events (MACCE) were determined as the clinical endpoints. RESULTS A total of 281 consecutive patients who met the study criteria and underwent elective or emergency transfemoral TAVI using the self-expandable CoreValve Evolut valve were included. 176 consecutive patients implanted with the classical TCV technique and 105 consecutive patients implanted with the COP technique were compared. Compared with the TCV group, patients in the COP group had lower PPMI (3.8% vs. 10.8%, p = 0.039), in-hospital mortality (1.9% vs. 8.5%, p = 0.018), and 1-year death (4.8% versus 18.8%, p = 0.001), and MACCE rates (12.4% vs 31.3%, p < 0.001). CONCLUSION The COP technique may help to reduce the conduction disturbances, PPMI requirement and complication rates that may develop following TAVI. In addition, it is an interesting result that it reduces mortality and MACCE rates in long-term follow-ups.
Collapse
Affiliation(s)
- Tuncay Güzel
- Department of Cardiology, Health Science University, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey.
| | - Muhammed Demir
- Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Adem Aktan
- Department of Cardiology, Mardin Training and Research Hospital, Mardin, Turkey
| | - Baran Arık
- Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Lokman Argun
- Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Kamran İldırımlı
- Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Mihriban Sütcü
- Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Bayram Arslan
- Department of Cardiology, Ergani State Hospital, Diyarbakir, Turkey
| | - Mehmet Özbek
- Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Raif Kılıç
- Department of Cardiology, Diyarlife Hospital, Diyarbakir, Turkey
| | - Burhan Aslan
- Department of Cardiology, Health Science University, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey
| | - Mesut Gitmez
- Department of Cardiology, Batman Training and Research Hospital, Batman, Turkey
| | - Mehmet Karaçalılar
- Department of Cardiovascular Surgery, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - Çayan Çakır
- Department of Cardiology, Bismil State Hospital, Diyarbakir, Turkey
| | - Faruk Ertaş
- Department of Cardiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| |
Collapse
|
5
|
Embolic Protection with the TriGuard 3 System in Nonagenarian Patients Undergoing Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis. J Clin Med 2022; 11:jcm11072003. [PMID: 35407611 PMCID: PMC8999484 DOI: 10.3390/jcm11072003] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Revised: 03/21/2022] [Accepted: 03/28/2022] [Indexed: 02/06/2023] Open
Abstract
Background: Transcatheter aortic valve replacement (TAVR) improves the survival and life quality of nonagenarian patients with aortic stenosis. Stroke remains one of the most worrisome complications following TAVR. Cerebral embolic protection devices (CEPDs) may reduce neurological complications after TAVR. This study evaluated the safety and efficacy of CEPDs during TAVR in nonagenarian patients. Methods: Between January 2018 and October 2021, 869 patients underwent transfemoral TAVR (TF-TAVR) at our center. Of these, 51 (5.9%) patients were older than ninety years. In 33 consecutive nonagenarian patients, TF-TAVR was implanted without CEPDs using balloon-expandable valves (BEVs) and self-expandable valves (SEVs). Eighteen consecutive nonagenarians underwent TF-TAVR using a CEPD (CP group). Follow up period was in-hospital or 30 days after the procedure, respectively. Results: Minor access site complications occurred in two patients (3.9%) and were not CEPD-associated. Postinterventional delirium occurred in nine patients (17.6%). Periprocedural minor non-disabling stroke and delirium occurred in ten patients (19.6%). Periprocedural major fatal stroke occurred in two patients in the BEV group (3.9%). Two patients in the BEV group died due to postinterventional pneumonia with sepsis. The mortality rate was 7.8%. The results did not differ between the groups. Conclusions: Age alone is no longer a contraindication for TAVR. CEPD using the Triguard 3 system in nonagenarian TAVR patients was feasible and safe and did not increase access site complications.
Collapse
|
6
|
Doldi PM, Stolz L, Escher F, Steffen J, Gmeiner J, Roden D, Linnemann M, Löw K, Deseive S, Stocker TJ, Orban M, Theiss H, Rizas K, Curta A, Sadoni S, Buech J, Joskowiak D, Peterss S, Hagl C, Massberg S, Hausleiter J, Braun D. Transcatheter Aortic Valve Replacement with the Self-Expandable Core Valve Evolut Prosthesis Using the Cusp-Overlap vs. Tricusp-View. J Clin Med 2022; 11:jcm11061561. [PMID: 35329887 PMCID: PMC8953752 DOI: 10.3390/jcm11061561] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 01/31/2022] [Accepted: 03/10/2022] [Indexed: 01/27/2023] Open
Abstract
Despite the rapid increase in experience and technological improvement, the incidence of conduction disturbances in patients undergoing transcatheter aortic valve replacement (TAVR) with the self-expandable CoreValve Evolut valve remains high. Recently, a cusp-overlap view (COP) implantation technique has been proposed for TAVR with self-expandable valves offering an improved visualization during valve expansion compared to the three-cusp view (TCV). This study aims to systematically analyze procedural outcomes of TAVR patients treated with the CoreValve Evolut valve using a COP compared to TCV in a high-volume center. The primary endpoint was technical success according the 2021 VARC-3 criteria. A total of 122 consecutive patients (61 pts. TCV: April 2019 to November 2020; 61 pts. COP: December 2020 to October 2021) that underwent TAVR with the CoreValve Evolut prosthesis were included in this analysis. Although there was no difference in the primary endpoint technical success between TCV and COP patients (93.4% vs. 90.2%, OR 0.65, 95% CI 0.16, 2.4, p = 0.51), we observed a significantly lower risk for permanent pacemaker implantation (PPI) among COP patients (TCV: 27.9% vs. COP: 13.1%, OR 0.39, 95% CI 0.15, 0.97, p = 0.047). Implantation of the CoreValve Evolut prosthesis using the COP might help to reduce the rate of PPI following TAVR.
Collapse
Affiliation(s)
- Philipp Maximilian Doldi
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
- Correspondence:
| | - Lukas Stolz
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
| | - Felix Escher
- Klinik und Poliklinik für Radiologie, Klinikum der Universität München, 81377 Munich, Germany; (F.E.); (A.C.)
| | - Julius Steffen
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
| | - Jonas Gmeiner
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
| | - Daniel Roden
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
| | - Marie Linnemann
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
| | - Kornelia Löw
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
| | - Simon Deseive
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
| | - Thomas J. Stocker
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
| | - Martin Orban
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
| | - Hans Theiss
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
| | - Konstantinos Rizas
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
| | - Adrian Curta
- Klinik und Poliklinik für Radiologie, Klinikum der Universität München, 81377 Munich, Germany; (F.E.); (A.C.)
| | - Sebastian Sadoni
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, 81377 Munich, Germany; (S.S.); (J.B.); (D.J.); (S.P.); (C.H.)
| | - Joscha Buech
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, 81377 Munich, Germany; (S.S.); (J.B.); (D.J.); (S.P.); (C.H.)
| | - Dominik Joskowiak
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, 81377 Munich, Germany; (S.S.); (J.B.); (D.J.); (S.P.); (C.H.)
| | - Sven Peterss
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, 81377 Munich, Germany; (S.S.); (J.B.); (D.J.); (S.P.); (C.H.)
| | - Christian Hagl
- Herzchirurgische Klinik und Poliklinik, Klinikum der Universität München, 81377 Munich, Germany; (S.S.); (J.B.); (D.J.); (S.P.); (C.H.)
| | - Steffen Massberg
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
| | - Jörg Hausleiter
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
| | - Daniel Braun
- Medizinische Klinik und Poliklinik I, Klinikum der Universität München, 81377 Munich, Germany; (L.S.); (J.S.); (J.G.); (D.R.); (M.L.); (K.L.); (S.D.); (T.J.S.); (M.O.); (H.T.); (K.R.); (S.M.); (J.H.); (D.B.)
- German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, 80539 Munich, Germany
| |
Collapse
|